Literature DB >> 2078410

Oligopeptide inhibitors of HIV-induced syncytium formation.

R J Owens1, C C Tanner, M J Mulligan, R V Srinivas, R W Compans.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein is essential for virus entry and the formation of multinucleated giant cells by cell fusion, one of the major virus-induced cytopathic effects. To study the effects of potential fusion inhibitors, a vaccinia virus recombinant expressing the envelope glycoprotein was generated and used to infect HeLa CD4+ cells. Syncytium induction was observed as early as 4 h postinfection and continued until the entire monolayer was fused. The N-terminus of the gp41 subunit of the HIV envelope protein is very hydrophobic, and appears to be involved in virus-induced membrane fusion. We synthesized several oligopeptide analogs of the N-terminal region of gp41 and determined their ability to inhibit HIV-induced cell fusion in CD4+ HeLa cells. A hexapeptide which was identical in amino acid sequence to the N-terminus of gp41 was found to completely inhibit cell fusion, whereas peptides with altered sequences showed reduced inhibitory activity. These peptides had no effect on protein synthesis, processing, or transport to the cell surface, and showed no signs of toxicity to cells even at very high concentrations. These results indicate that oligopeptides which are homologous to the fusion peptide of HIV inhibit virus-induced cytopathology, and should be evaluated further as potential antiviral agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2078410     DOI: 10.1089/aid.1990.6.1289

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  15 in total

Review 1.  T-cell antigen receptor (TCR) transmembrane peptides: A new paradigm for the treatment of autoimmune diseases.

Authors:  Nicholas Manolios; Marina Ali; Vera Bender
Journal:  Cell Adh Migr       Date:  2010-04-30       Impact factor: 3.405

Review 2.  Role of lipids in virus replication.

Authors:  Maier Lorizate; Hans-Georg Kräusslich
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-10-01       Impact factor: 10.005

Review 3.  Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy.

Authors:  Himanshu Garg; Mathias Viard; Amy Jacobs; Robert Blumenthal
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

4.  Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro.

Authors:  Jia Ma; Suzanne Kennedy-Stoskopf; Jesse M Jaynes; Linda M Thurmond; Wayne A Tompkins
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor.

Authors:  P F Lin; H Samanta; C M Bechtold; C A Deminie; A K Patick; M Alam; K Riccardi; R E Rose; R J White; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

6.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Authors:  C T Wild; D C Shugars; T K Greenwell; C B McDanal; T J Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

7.  Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.

Authors:  R L Willey; M A Martin; K W Peden
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

8.  Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion.

Authors:  H Schaal; M Klein; P Gehrmann; O Adams; A Scheid
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

9.  Peptide inhibition of human cytomegalovirus infection.

Authors:  Lilia I Melnik; Robert F Garry; Cindy A Morris
Journal:  Virol J       Date:  2011-02-22       Impact factor: 4.099

Review 10.  Peptide-based Fusion Inhibitors for Preventing the Six-helix Bundle Formation of Class I Fusion Proteins: HIV and Beyond.

Authors:  Ajit Monteiro; Karl O A Yu; Mark D Hicar
Journal:  Curr HIV Res       Date:  2021       Impact factor: 1.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.